Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
2022 driven by particularly strong performance from EntrestoⓇ,
KesimptaⓇ, KisqaliⓇ and PluvictoⓇ
FY sales¹
Entresto *
Sales
USD million
4,644
sacubitilvalsartan
Kesimpta *
(ofatumumab)
1,092
KISQALI✶
1,231
294
ribociclib
*
271
PLUVICTO™
271
SCEMBLIX *
149
(asciminih) ago
142
*
*LEQVIO®
112
100
Tafinlar. Mekinist.
1,770
77
bohrt
MAYZENT.
357
(siponimod) tablets
76
ILARIS
(canakinumab)
1,133
74
PROMACTA®
(eltrombopag)
Cosentyx
2,088
72
*
4,788
70
(secukinumab
* Please see subsequent slides
Growth vs. PY
USD million
Growth vs. PY
CC
GROWTH
1,096
720
37%
200%
2022:
Strong growth (+60% cc)
38%
nm
2023 and beyond:
nm
Expect continued
nm
strong growth
11%
32%
15%
9%
5%
Expect LCM to accelerate growth
Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 50 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
nm - not meaningful. LCM-life cycle management.
22 Investor Relations | Q4 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation